M&A / Deals Zymeworks cuts deal to buy Theravance for $929m in cash PharmaphorumZymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.Read full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaphorum Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year. Read full story Post navigation Previous: BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefitNext: UK partners with Eli Lilly on obesity plan Related Stories M&A / Deals Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset pharminent August 12, 2026 M&A / Deals Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront pharminent August 11, 2026 M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026
